SCHEMBL3038698

SCHEMBL3038698

CN(CCO)c1ccc(C=Cc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
MMP14 P50281 1/20 0.49
ALDH1A1 P00352 4/20 0.49
PTGS2 P35354 6/20 0.49
PTGS1 P23219 2/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
APP P05067 1/20 0.47
FBP1 P09467 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
CYP19A1 P11511 2/20 0.45
KDM4E B2RXH2 3/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PSMD14 O00487 1/20 0.44
ALPL P05186 1/20 0.44
ALPI P09923 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038695 1.00 MAPT (0.57) MAPTMMP14ALDH1A1PTGS2PTGS1
SCHEMBL1729465 0.91 MAPT (0.68) MAPTMMP14ALDH1A1CRHBPCRHR2
SCHEMBL25223749 0.88 MAPT (0.49) MAPTMMP14ALDH1A1PTGS2PTGS1
SCHEMBL8905953 0.88 MAPT (0.53) MAPTMMP14ALDH1A1PTGS2PTGS1
SCHEMBL8905957 0.88 MAPT (0.53) MAPTMMP14ALDH1A1PTGS2PTGS1
SCHEMBL25194702 0.87 MAOB (0.63) MAPTALDH1A1CRHBPCRHR2
SCHEMBL10046634 0.87 MAOB (0.63) MAPTALDH1A1CRHBPCRHR2
SCHEMBL9847342 0.87 MAPT (0.68) MAPTMMP14ALDH1A1PTGS2PTGS1
SCHEMBL8422918 0.85 PTGS2 (0.51) MAPTALDH1A1PTGS2PTGS1NPC1
SCHEMBL8645474 0.85 PTGS2 (0.51) MAPTALDH1A1PTGS2PTGS1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7537715-B2 Self-poled electro-optic and nonlinear optical polymer, method of manufacturing the polymer, and film manufactured from the polymer ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2009-05-26 US claimed
EP-1651237-A4 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS JOHNSON & JOHNSON CONSUMER (US) 2008-10-01 EP claimed
US-20060131548-A1 Self-poled electro-optic and nonlinear optical polymer, method of manufacturing the polymer, and film manufactured from the polymer ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2006-06-22 US claimed
EP-1651237-A2 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS Galileo Pharmaceuticals, Inc. (US) 2006-05-03 EP claimed
WO-2005016270-A2 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS GALILEO PHARMACEUTICALS, INC. (US) 2005-02-24 WO claimed
US-20050032751-A1 Methods for treatment of dermatological conditions JOHNSON & JOHNSON CONSUMER INC. 2005-02-10 US claimed
US-20100202989-A1 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS WANG BING 2010-08-12 US disclosed
US-7737179-B2 Methods for treatment of dermatological conditions J&J CONSUMER COMPANIES, INC. (US) 2010-06-15 US disclosed
US-7537715-B2 Self-poled electro-optic and nonlinear optical polymer, method of manufacturing the polymer, and film manufactured from the polymer ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2009-05-26 US disclosed
EP-1651237-A4 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS JOHNSON & JOHNSON CONSUMER (US) 2008-10-01 EP disclosed
US-7135543-B2 Polyamic ester having moieties of electro optic and nonlinear optical compound in side chains as an electro optic and nonlinear optical polymer, manufacturing method therefor and film manufactured therefrom ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2006-11-14 US disclosed
US-20060131548-A1 Self-poled electro-optic and nonlinear optical polymer, method of manufacturing the polymer, and film manufactured from the polymer ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2006-06-22 US disclosed
EP-1651237-A2 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS Galileo Pharmaceuticals, Inc. (US) 2006-05-03 EP disclosed
US-5007696-A Electro-optic channel waveguide LOCKHEED MISSILES & SPACE COMPANY, INC. (US) 1991-04-16 US disclosed
US-5006285-A Electro-optic channel waveguide LOCKHEED MISSILES & SPACE COMPANY, INC. (US) 1991-04-09 US disclosed
US-4957655-A OPTICAL SWITCHES, LIGHT MODULATOR, VINYL HALIDE-ACRYLIC ESTER COPOLYMER WITH PENDANT SIDECHAIN HOECHST CELANESE CORP. (US) 1990-09-18 US disclosed
EP-0378185-A2 Copolymeric nonlinear optical media HOECHST CELANESE CORPORATION (US) 1990-07-18 EP disclosed
US-4865430-A Acrylic copolymers exhibiting nonlinear optical response HOECHST CELANESE CORP. (US) 1989-09-12 US disclosed
EP-0312856-A1 Acrylic copolymers exhibiting nonlinear optical response HOECHST CELANESE CORPORATION (US) 1989-04-26 EP disclosed
US-4808332-A Acrylic copolymers exhibiting nonlinear optical response HOECHST CELANESE CORP. (US) 1989-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100202989-A1 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS KRT18, CUTA, TUBB1 MAPT 1044/4885MMP14 778/4885ALDH1A1 458/4885
US-20050032751-A1 Methods for treatment of dermatological conditions KRT18, CUTA, TUBB1 MAPT 1044/4885MMP14 778/4885ALDH1A1 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.